Literature DB >> 8951184

The new generation of antiepileptic drugs: advantages and disadvantages.

E Perucca1.   

Abstract

1. After a hiatus of over 20 years, several new antiepileptic drugs (vigabatrin, lamotrigine, gabapentin, oxcarbazepine, topiramate, felbamate, zonisamide and tiagabine) have reached or approached the registration phase. 2. Compared with older agents, many new drugs exhibit simpler pharmacokinetics. This is especially true for vigabatrin and gabapentin, which are renally eliminated and have a low interaction potential. 3. Unlike most of the older agents, vigabatrin, lamotrigine, gabapentin and tiagabine are devoid of significant enzyme inducing or inhibiting properties. Topiramate, oxcarbazepine and felbamate may induce the metabolism of steroid oral contraceptives. In addition, felbamate also acts as a metabolic inhibitor. 4. To date, the efficacy of new drugs has been evaluated extensively only under add-on conditions in patients with partial seizures (with or without secondary generalization) refractory to conventional treatment. However, there is evidence that lamotrigine, zonisamide, felbamate and, possibly, topiramate may also be effective in generalized epilepsies. 5. In placebo-controlled studies, typically between 15 and 40% of patients with difficult-to-treat partial epilepsy have shown an improvement (defined as a 50% or greater decrease in seizure frequency) after addition of a new drug. Only a small minority of these patients achieved complete seizure control. 6. Compared with older agents, some of the new drugs may have a better tolerability profile. Felbamate, however, has been associated with a high risk of aplastic anaemia and hepatotoxicity. 7. At present, the main use of the new agents is in patients refractory to first-line drugs such as carbamazepine or valproate, and further studies are required to characterize their activity spectrum as well as their potential value in monotherapy. In most patients, new drugs cannot be recommended for first-line use until evidence is obtained that potential advantages in tolerability or ease of use outweigh the drawback of their high cost.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8951184     DOI: 10.1111/j.1365-2125.1996.tb00107.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  13 in total

1.  Increase in dihydroxycarbamazepine serum levels in patients co-medicated with oxcarbazepine and lamotrigine.

Authors:  N Guénault; P Odou; H Robert
Journal:  Eur J Clin Pharmacol       Date:  2003-10-24       Impact factor: 2.953

Review 2.  Drug-induced myelosuppression : diagnosis and management.

Authors:  Peter J Carey
Journal:  Drug Saf       Date:  2003       Impact factor: 5.606

Review 3.  Treatment of concomitant illnesses in patients receiving anticonvulsants: drug interactions of clinical significance.

Authors:  P Loiseau
Journal:  Drug Saf       Date:  1998-12       Impact factor: 5.606

4.  The effect of polymorphic metabolism enzymes on serum phenytoin level.

Authors:  Aydan Ozkaynakci; Medine Idrizoglu Gulcebi; Deniz Ergeç; Korkut Ulucan; Mustafa Uzan; Cigdem Ozkara; Ilter Guney; Filiz Yilmaz Onat
Journal:  Neurol Sci       Date:  2014-10-14       Impact factor: 3.307

Review 5.  Is there a role for therapeutic drug monitoring of new anticonvulsants?

Authors:  E Perucca
Journal:  Clin Pharmacokinet       Date:  2000-03       Impact factor: 6.447

6.  Drug burden index to define the burden of medicines in older adults with intellectual disabilities: An observational cross-sectional study.

Authors:  Juliette O'Connell; Éilish Burke; Niamh Mulryan; Claire O'Dwyer; Clare Donegan; Philip McCallion; Mary McCarron; Martin C Henman; Máire O'Dwyer
Journal:  Br J Clin Pharmacol       Date:  2018-01-05       Impact factor: 4.335

7.  [Which factors have an impact on levetiracetam serum concentrations? An analysis in 163 patients with epilepsy].

Authors:  J Bauer; C Pfeiffer; W Burr
Journal:  Nervenarzt       Date:  2010-04       Impact factor: 1.214

Review 8.  Harnessing the clinical potential of antiepileptic drug therapy: dosage optimisation.

Authors:  E Perucca; O Dulac; S Shorvon; T Tomson
Journal:  CNS Drugs       Date:  2001       Impact factor: 5.749

Review 9.  Clinical pharmacokinetics of new-generation antiepileptic drugs at the extremes of age.

Authors:  Emilio Perucca
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

10.  Effect of magnesium oxide on the activity of standard anti-epileptic drugs against experimental seizures in rats.

Authors:  Priti Pravin Dhande; Rajani Shrikant Ranade; Balasaheb B Ghongane
Journal:  Indian J Pharmacol       Date:  2009-12       Impact factor: 1.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.